Raffaella Iurlaro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raffaella Iurlaro has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Ester Bonfill-Teixidor
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain. 1
22 shared publications - Joan Seoane
Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron University Hospital, 08035 Barcelona, Spain
22 shared publications - Alexandra Arias
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain. 1
15 shared publications - Almudena Neva-Alejo
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain. 1
12 shared publications - Francisco Martínez-Ricarte
Vall D'Hebron University Hospital, Barcelona, Spain
10 shared publications - Josep Tabernero
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
10 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Purpose:Leukemia inhibitory factor (LIF) is a multifunctional cytokine with numerous reported roles in cancer and is thought to drive tumor development and progression. Characterization of LIF and clinical-stage LIF inhibitors would increase our understanding of LIF as a therapeutic target.Experimental Design:We first tested the association of LIF expression with transcript signatures representing multiple processes regulating tumor development and progression. Next, we developed MSC-1, a high-affinity therapeutic antibody that potently inhibits LIF signaling and tested it in immune competent animal models of cancer.Results:LIF was associated with signatures of tumor-associated macrophages (TAM) across 7,769 tumor samples spanning 22 solid tumor indications. In human tumors, LIF receptor was highly expressed within the macrophage compartment and LIF treatment drove macrophages to acquire immunosuppressive capacity. MSC-1 potently inhibited LIF signaling by binding an epitope that overlaps with the gp130 receptor binding site on LIF. MSC-1 showed monotherapy efficacy in vivo and drove TAMs to acquire antitumor and proinflammatory function in syngeneic colon cancer mouse models. Combining MSC-1 with anti-PD1 leads to strong antitumor response and a long-term tumor-free survival in a significant proportion of treated mice.Conclusions:Overall, our findings highlight LIF as a therapeutic target for cancer immunotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Purpose:Leukemia inhibitory factor (LIF) is a multifunctional cytokine with numerous reported roles in cancer and is thought to drive tumor development and progression. Characterization of LIF and clinical-stage LIF inhibitors would increase our understanding of LIF as a therapeutic target.Experimental Design:We first tested the association of LIF expression with transcript signatures representing multiple processes regulating tumor development and progression. Next, we developed MSC-1, a high-affinity therapeutic antibody that potently inhibits LIF signaling and tested it in immune competent animal models of cancer.Results:LIF was associated with signatures of tumor-associated macrophages (TAM) across 7,769 tumor samples spanning 22 solid tumor indications. In human tumors, LIF receptor was highly expressed within the macrophage compartment and LIF treatment drove macrophages to acquire immunosuppressive capacity. MSC-1 potently inhibited LIF signaling by binding an epitope that overlaps with the gp130 receptor binding site on LIF. MSC-1 showed monotherapy efficacy in vivo and drove TAMs to acquire antitumor and proinflammatory function in syngeneic colon cancer mouse models. Combining MSC-1 with anti-PD1 leads to strong antitumor response and a long-term tumor-free survival in a significant proportion of treated mice.Conclusions:Overall, our findings highlight LIF as a therapeutic target for cancer immunotherapy.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1, Supplementary methods
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1, Supplementary methods
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose:Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer.Experimental Design:We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment.Results:We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI.Conclusions:Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose:Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer.Experimental Design:We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment.Results:We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI.Conclusions:Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 30 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4505-4516
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 30 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4505-4516
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Supplementary Table 1: Description of TCGA derived mRNA expression cohorts used to examine LIF expression and associated transcript signaturesSupplementary Table 2: Transcription signatures used to identify biological processes and cell types correlated with LIF expression.Supplementary Table 3: GSEA results of REACTOME pathway gene sets for enriched gene sets in LIF treated macrophages. Supplementary Table 4: Leading edge genes selected from GSEA analysis of LIF treated macrophages with REACTOME pathway gene sets Supplementary Table 5: Summary of data collection statistics for crystal structures of MSC-1:LIF co-complex Supplementary Table 6: Summary of interactions between MSC-1 and LIF